6th Gene Therapy for Ophthalmic Disorders Summit | December 2 - 4, 2025 | Raleigh, NC
December 2 - 4, 2025 - NC USHanson Wade
info@hansonwade.com
Phone:(+1) 617 455 4188
Unprecedented momentum is building in 2025: - Kriya Therapeutics advancing through preclinical development - Opus Genetics and SpliceBio entering their early trials - Ocugen, 4D Molecular Therapeutics, and AbbVie racing towards BLA approval This surge creates an urgent demand to mitigate critical bottlenecks like endpoints, funding, delivery, and more. The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh, North Carolina, as the leading industry-specific event uniting biopharma scientists and strategists to tackle these challenges head-on. Join us to unlock the next breakthrough beyond Luxturna and accelerate your therapy to patients. What is the 6th Gene Therapy for Ophthalmic Disorders Summit About? With vision loss progressing rapidly in many eye diseases, and irreversible damage threatening patients with slower-onset conditions, gene therapies represent a critical one-time intervention to preserve sight. The 6th Gene Therapy for Ophthalmic Disorders Summit brings together the latest breakthroughs driving this urgent field forward. This year's agenda features exclusive preclinical data from emerging leaders such as Opus Genetics, Coave Therapeutics, and Axovia Therapeutics, alongside 2025 clinical updates from Ocugen, Adverum Biotechnologies, and Beacon Therapeutics. Don't miss groundbreaking data reveals and our dedicated focus on securing funding, advancing AAV delivery, and optimizing patient retention strategies - factors that are revolutionizing trial outcomes and shaping regulatory success Time: 8:00 AM - 5:00 PM